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Abstract
Epigenetic modifications influence gene expression and thereby play a pivotal role in
development and disease. Misregulation and mutations in the DAX-1 gene, or Dosage-Sensitive
Sex Reversal, Adrenal Hypoplasia Congenita, Critical Region on the X chromosome, gene 1, have
been implicated in Adrenal Hypoplasia Congenita (AHC) and Dosage Sensitive Sex Reversal
(DSS). The orphan nuclear hormone receptor DAX-1 is expressed predominantly in tissues such
as the testes, ovaries, breast, adrenal cortex, and lung. Critically, DAX-1 may serve as an indicator
of aberrant growth in these tissues. Here we hypothesize that DAX-1 is epigenetically regulated,
specifically in cancer cells, thereby reducing its expression. In a survey of several human cancer
cell lines, the methylation status of the promoter region of DAX-1 was investigated in order to
determine whether epigenetic control played a role in repressing DAX-1 gene expression. Through
molecular techniques such as qPCR and western blots, differential expression of DAX-1 in human
cell lines was confirmed. Additionally, methylation specific restriction enzyme analysis and
bisulfite sequencing identified the location of methylation in breast, adrenal, lung, liver, and kidney
cancer cell lines. Following these experiments, a correlation of the methylation status of the DAX1 promoter and DAX-1 expression is evident. In tandem with bisulfite sequence analysis,
chromatin immunoprecipitation experiments elucidated a primary region of interest in which
methylation may be critical to the silencing of DAX-1 gene expression. Centered around the
transcriptional start site, a stark difference in methyl binding protein occupancy between cancerous
and noncancerous breast tissue was identified and likely plays a critical role in gene repression via
methylation. Ultimately, this research aims to elucidate the role of epigenetic regulation in gene
expression as well as further our understanding of the role of DAX-1 in human cancers.
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Chapter 1: Introduction
The epigenome is a collection of heritable modifications to DNA that results in genotypic
and phenotypic variability. Physiologically, these modifications are common occurrences
observed between different types of cells within the body. However, aberrant epigenetic mutations
can lead to disease and in some cases, be used as an identifier of cancer. Studies of epigenetics
have elucidated a great deal of information about both the genesis of disease as well as its
heritability. Specifically, cancer epigenetics is a popular new topic on the forefront of scientific
research. However, before understanding the mutations and possible misregulation brought forth
through epigenetic modifications, it is critical to understand the basic process. My thesis focuses
on the epigenetic regulation of the DAX-1 (Dosage-Sensitive Sex Reversal, Adrenal Hypoplasia
Congenita, Critical Region on the X chromosome, gene 1) gene and the fundamental role of
epigenetics in gene expression. Central to this thesis research is understanding the gene, its current
implications on growth and development, and how epigenetics may be playing a significant role.
I have investigated key commonalities found in breast, prostate, lung, adrenal, and liver cancer
(Conde et al., 2004; He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al., 2018;
Kumata et al., 2018). All of these forms of cancer express, to varying degrees, the DAX-1 gene.
Nevertheless, the exact role DAX-1 plays in each of these cancers is not yet fully understood. The
goal of this thesis project is to investigate the epigenetic mechanisms that control DAX-1 gene
expression in normal as well as cancer cells lines.

11

Background
Epigenetic modifications are an important mechanism that regulate gene expression during
development, but these modifications also play a key role in diseases such as diabetes,
cardiovascular disease, and cancer. Before delving into how epigenetics plays a role in
development and disease, it is important to first define epigenetics, epigenetic modifications, and
the epigenome. Epigenetics has been of prominent interest for the past few decades, however, an
agreed upon definition has yet to emerge. Starting in the late 1950s, epigenetics was defined as the
study of genotypes that lead to specific phenotypes in development (Bird, 2002, 2007). However,
more recently in the 1990s, a new interpretation arose when Arthur Riggs and colleagues defined
epigenetics as the heritable modifications to genes that are beyond what the DNA encrypts (Bird,
2007; Russo et al., 1996; Waddington, 2014). Further debates came in the early 2000s, as
epigenetics took on a new form as a biomarker and possible means of diagnosis. Alternatively,
epigenetics was also defined as “all the heritable changes in gene regulation other than nucleotide
sequence and chromatin organization that depend on the DNA sequences itself” (Abi Khalil, 2014;
Egger et al., 2004; Rodenhiser & Mann, 2006). The increasing diversity in defining epigenetics
has led some scientists to call for a new ‘standard’ that all epigeneticists can utilize. In 2007, a
modified statement was suggested, one that encompassed many schools of thought: “the structural
adaptation of chromosomal regions so as to register, signal or perpetuate altered activity state”
(Bird, 2007). Although discrepancies continue, the field of epigenomics has begun to answer
questions regarding heritable traits. Newer interpretations have evolved and epigenetics is quickly
becoming the science that can explain how cells adapt to and are altered by their environment
through modifications of the gene that lead to phenotypic differences not expressed in the genotype
(Ordovás & Smith, 2010; Turan et al., 2010). For the purpose of the research outlined in this thesis,
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I will focus on the resulting epigenetic modification, rather than the origin of that change.
Epigenetic modifications are post-translational changes in the DNA sequence that control gene
expression. There are three primary classes of epigenetic modification mechanisms in human cells:
DNA methylation, histone modification, and micro-RNA based mechanisms. All three
mechanisms are often interrelated and pivotal to cell differentiation, gene activity, and aging (Abi
Khalil, 2014; Jintaridth & Mutirangura, 2010; Kwabi-Addo et al., 2007; Murgatroyd & Spengler,
2011).
As fundamental mechanisms to gene expression, epigenetic modifications are heritable,
occasionally reversible, and have been tied to disease. Among some of the more studied cases,
epigenetics has been associated with developmental diseases, mental illness, cardiovascular
disease (CVD), and cancer (Ball et al., 2009; Bird, 2002; Brown et al., 2008; Eckhardt et al., 2006;
Halušková, 2009; Hansen et al., 2011; He et al., 2008; Jintaridth & Mutirangura, 2010; Kerachian
et al., 2020; Kudryavtseva et al., 2018; Kwabi-Addo et al., 2007; Manel, 2008; Manoochehri et
al., 2016; Martin et al., 2011; Murgatroyd & Spengler, 2011; Rakyan et al., 2004; Robertson, 2005;
Suzuki & Bird, 2008; van IJzendoorn et al., 2011; E. M. Wong et al., 2020; Zhu & Yao, 2007).
Early development is heavily impacted by epigenetic marks that influence gene expression and
cell differentiation (Cedar & Bergman, 2011). Critical cellular processes, such as hematopoietic
cell development, are mediated by epigenetic changes that include histone deacetylation and
demethylation. These modification patterns determine a cell's fate to either remain in a pluripotent
state or commit to a specific cell type. For example, the decision required for a cell to progress
towards myeloid versus lymphoid differentiation depends on the expression of the V(D)J gene
segments and the ‘assembly’ of antibodies through V(D)J recombination in both B and T cells.
Notably, this process is regulated by histone activation (Cedar & Bergman, 2011). In neurological
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development, epigenetic alteration of gene expression in early years has been shown to impact
brain function and mental illness later in life (Murgatroyd & Spengler, 2011). Similar to the
differentiation produced by V(D)J recombination, neurons contain the same DNA but carry out
diverse functions due to differential gene expression. Pre- and postnatal development is influenced
by environmental conditions. Therefore, gene expression can be mediated by epigenetic
modifications brought about not only through natural mechanisms, but also external influences
such as maternal care or early life adversity and stress. Such variations to the epigenome caused
by gene silencing or inappropriate expression have been identified in neurodegenerative diseases,
mental retardation, and schizophrenia. Still, the impacts of epigenetic modification and
dysregulation are not limited to developmental diseases. As the global leading cause of death,
cardiovascular disease is a prominent target for therapeutic research (Cardiovascular Diseases,
n.d.). Previous studies have linked all three forms of epigenetic modifications (methylation,
histone modification, and micro-RNA based mechanisms) to various cardiovascular diseases
including heart hypertrophy, heart failure, arrhythmias, and vascular diseases (Abi Khalil, 2014).
In some instances, the epigenetic involvement is more direct, impacting inflammation and vascular
function. In other cases, the role of epigenetics is more pertinent through the lens of increased risk
factors (Abi Khalil, 2014; Ordovás & Smith, 2010). Environmental and behavioral factors such as
pollution, smoking, stress, nutrition and circadian rhythm have been shown to influence the risk
and progression of CVDs.
Although the correlation between epigenetics and disease has been established, uncertainty
remains around whether epigenetics is a precursor to disease or the result of a disease (Bell &
Spector, 2011; Martin et al., 2011). It is evident that aberrant epigenetic modifications overlap
with disease; therefore an addendum to the definition of epigenetics is inevitably required: “one
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caused by a stable alteration in the epigenetic state of a gene (epimutation) without any
contributory genetic mutation” (Martin et al., 2011). Although this may seem to lead towards a
causal relationship between epigenetics and disease, this is not the case. Environment plays a
fundamental role in development, and epigenetics is the mechanism for rapid cellular adaptation
(Bell & Spector, 2011; Murgatroyd & Spengler, 2011; van IJzendoorn et al., 2011). Therefore, it
may be the environment or the disease that leads to the aberrant modifications, and not the other
way around. This line of behavioral epigenetic research can often unravel into a question of nature
versus nurture, and which came first. Regardless, the theme remains that epigenetics is prevalent
in disease, particularly those that correlate with gene silencing via DNA methylation (Figure 1.1).
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Figure 1.1 The interconnection of genetic, epigenetic, the environment and phenotypic
results. Figure adapted from van IJzendoorn et al., 2011 depicting the theory of behavioral
epigenetics, where the outcome of modification by any of these three factors is a phenotypical
alteration.
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DNA Methylation
The focus of this thesis research is on one particular type of epigenetic modification: DNA
methylation. DNA methylation is the process by which a methyl group is transferred onto the C5
position of a cytosine (Moore et al., 2013; Zeisel, 2009). The transfer can be done by DNA
Methyltransferases (DNMTs), methyl-CpG binding domain proteins, and the Kaiso family of
proteins (Fournier et al., 2012). The Kaiso family of proteins are unique in their ability to bind
both methylated CpG-containing DNA sequences, as well as non-methylatable regions without
CpG islands. Kaiso family proteins can bind to sequence-specific methylated regions of promoters
and thereby repress transcription (Fournier et al., 2012; Sasai et al., 2010). Cytosine DNA
methylation is crucial to our understanding of human development as it is the only known DNA
modification fundamental to mammalian growth (Jones & Takai, 2001; Robertson, 2005).
Following the completion of the Human Genome Project in 2003, new attention was granted to
the Human Epigenome Project because it became clear that epigenetic marks are heritable and
contribute significantly to embryonic development and phenotype expression (Rakyan et al., 2004;
Robertson, 2005). Functionally, DNA methylation often results in the silencing of gene expression
and promoter activity (Figure 1.2) (Bird, 2002; Moore et al., 2013; Suzuki & Bird, 2008; van
IJzendoorn et al., 2011).
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Figure 1.2 The biochemical reaction of cytosine methylation in DNA results in the silencing
of gene expression. Figure adapted from van IJzendoorn et al., 2011 and Zeisel, 2007; the addition
of CH3 to a cytosine molecule via a methyl binding protein (MBP) prevents the transcription factor
(TF) from initiating transcription and gene expression.
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This epigenetic mark caused by DNA methylation goes beyond differential expression of
genes necessary during development and underlies human disease, X-chromosome inactivation,
and genomic imprinting disorders (Egger et al., 2004; Halušková, 2009; Heard et al., 1997; E. Li
et al., 1992, 1993; Robertson, 2005; Weber et al., 2007). Looking more closely at some of the
conditions mentioned above, methylation has a prominent place in disease. Specifically in CVD,
hypermethylation associated with the epidermal growth factor receptor (EGFR) gene in animal
models correlates with aortic valve calcification that leads to cardiac hypertrophy (Abi Khalil,
2014). Furthermore, DNA hypomethylation in mice with atherosclerosis contrasts the
hypermethylation of estrogen receptor alpha (ERα) and estrogen receptor beta (ERß) genes found
in human patients with atherosclerosis (Abi Khalil, 2014). Although not fully understood,
differential methylation status appears to be an underlying mechanism of various examples of
CVD, yet this genetic contribution to CVD remains elusive. A better understanding of the
epigenetic regulation of genes associated with CVD may lead to a new path of prevention and
therapy (Ordovás & Smith, 2010). Heritable epigenetic modifications due to behavior such as
smoking may also increase CVD risk. In children exposed to tobacco smoke while still in the
womb, CpG islands (5’-C-phosphate-G-3’ regions in DNA) typically hypermethylated are
observed at a significantly reduced level of methylation (Breton et al., 2009; Ordovás & Smith,
2010). The possible connection of reduced methylation as an epigenetic adaptation to increase
predisposition to disease later in life may provide further understanding of CVD and risk
associated factors. Beyond CVD, DNA methylation patterns established during development,
particularly in the hippocampus, extend well into adulthood (Brown et al., 2008). The spatial
organization of and degrees of methylation impact physiological function and determination of
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cell type. In this way, the prenatal methylation by DNA methyltransferases influences the
hippocampus and development of the adult brain (van IJzendoorn et al., 2011).
Changes in methylation and methylation machinery leading to abnormal methylation status
of promoters and regulatory regions of gene expression underlie rare diseases of
immunodeficiency, centromeric instability, facial anomalies syndrome (ICF), and Rhett syndrome
(Jones & Takai, 2001). Aberrant epigenetic changes lead to other cognitive dysfunctions as well.
Synaptic plasticity from epigenetic regulation is misregulated in cases such as Alzheimer’s disease,
Huntington's disease, and psychiatric disorders including schizophrenia and addiction (Halušková,
2009). Ultimately, while more thoroughly researched in some diseases compared to others,
epigenetics - specifically methylation - may serve as possible biomarkers in development and
disease.
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Cancer Epigenetics
A disease that has plagued the world since Egyptian times and a medical undertaking since
the early 1900s, cancer has captivated the research world for many years. The National Cancer
Institute predicts that in 2020, approximately 1.8 million people will be diagnosed with cancer in
the US alone, and roughly 606,520 people will die of cancer (Cancer Statistics - National Cancer
Institute, 2015). As both a genetic and epigenetic disease, cancer studies attract a variety of
attention, with fields of research focusing on prevention, detection, and treatment. Previous
research in cancer epigenetics has demonstrated the power of tracing methylation status of
candidate genes (Halušková, 2009). For example, in the bladder, methylation of the Rb1 gene has
been investigated as a potential indicator for cancer progression and development (Halušková,
2009; Malekzadeh et al., 2009). Additionally, in the study of biomarkers for cancer screening and
prognostic markers, eight genes of interest have been identified in ovarian cancer (Halušková,
2009; Su et al., 2009; Zhang et al., 2008). Hypermethylation of DNA mismatch repair genes such
as human mutL homolog1 (hMLH1) and human mutS homolog 2 (hMSH2) in ovarian cancer were
identified as potential prognostic markers (Zhang et al., 2008). Furthermore, methylation status of
three genes from the secreted frizzled receptor proteins (SFRP1, SFRP 2, and SFRP 5) family,
SRY-box 1 (SOX1), paired box gene 1 (PAX1), and LIM homeobox transcription factor 1 alpha
(LMX1A) were investigated as markers for ovarian cancer screening and potential prognostic
indicators (Su et al., 2009). Downregulation of the SFRP family has also been linked to aberrant
activation of the Wnt signaling pathway which promotes tumor progression (Kawano & Kypta,
2003). Hypermethylation of genes in the SFRP family has also been implicated in multiple cancers,
specifically the hypermethylation of SFRP1 in hepatomas, of SFRP2 in gastric cancers, and of
SFRP4 in colorectal cancers (Cheng et al., 2007; Feng Han et al., 2006; Shih et al., 2007).
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With an abundance of research that continues to grow, cancer epigenetics has become a
very specific scientific niche that has been defined as “the study of somatically heritable changes
in molecular processes that influence the flow of information between the DNA of cancer cells
and their gene expression patterns” (Cancer Epigenetics - Latest Research and News | Nature,
n.d.). While this definition encompasses many fields of interest, including histone modifications
and nuclear organization in tumor cells, this thesis focuses specifically on DNA methylation. As
previously stated, DNA methylation is required for normal mammalian development, gene
regulation, genomic imprinting, and chromatin structure (Bird, 2002). Using DNA methylation
and subsequent alterations in gene expression is increasingly popular as a potential biomarker and
risk assessor for cancer (Kerachian et al., 2020; Verma & Manne, 2006; E. M. Wong et al., 2020).
Particular attention has been directed at analyzing the varying degrees of DNA methylations and
identifying patterns common amongst cancer forms. DNA methylation predominantly occurs in
three degrees of severity: hyper, hypo, and simple methylation. However, hundreds of
methylations can occur at a time at many locations on a strand of DNA. Identifying specific
methylation sites in cancer tissue versus normal tissues continues to be a source of screening and
prognostic evaluators. In squamous cell lung carcinoma, significant hypermethylation in tissue
derived from tumors versus non-tumor derived lung tissue has led to the identification of twentytwo methylation markers, across eight different genes (Anglim et al., 2008; Halušková, 2009).
Figure 1.3 compares the distribution and frequency of hypermethylation and hypomethylation in
colorectal cancer cells to that found in healthy tissue (Kerachian et al., 2020).
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Figure 1.3 Locations of hyper and hypomethylation in colorectal cancer. Figure from
Kerachian et al., 2020 showing a data summary schematic of the location and frequency of
hypermethylation and hypomethylation uncovered in colorectal cancer tissue as opposed to healthy
tissue. 71% of CpG islands have been hypermethylated in the cancerous tissue sampled.

23

Nuclear Hormone Receptors
Nuclear hormone receptors (NHRs) are a group of ligand activated transcription factors
that can bind to both steroid hormones and lipophilic, non-steroid hormones and serve as signal
transducing molecules in multicellular organisms (Lalli, 2014; McCabe, 2007; Vanden Heuvel,
2015). An overview of the ligand binding NHR pathway is shown in Figure 1.4, where an
extracellular hormone signal initiates a cascade reaction that travels through the cytoplasm and
into the nucleus where the NHR binds to DNA promoter regions and induces a change in gene
expression. NHRs control a broad range of processes, including the regulation of cell growth and
proliferation, cardiovascular function, reproduction and sexual determination in development, just
to name a few.
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Figure 1.4 Activation of the nuclear hormone receptor (NHR) pathway. Figure adapted from
Heskett, 2014 demonstrating the nuclear hormone pathway at a cellular level. The process begins
inside the cytoplasm where a hormone binds to the nuclear hormone receptor complex and
dimerizes. The dimer is actively transported into the nucleus where a coactivator attaches to the
dimer to assist in the binding of RNA polymerase. This complex attaches to the hormone response
element (HRE) region on the target gene and modifies gene expression.
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The functionality of NHRs follows their unique structure consisting primarily of two major
regions: the DNA Binding Domain (DBD) and the Ligand Binding Domain (LBD) (Figure 1.5).
The DBD, located near the N-terminus of most NHRs, is composed of two highly conserved zincfinger regions that mediate binding to specific DNA sequences typically located in the promoter
region of target genes. The DNA regions that are bound by a NHR are called hormone response
elements, or HREs, and consist of two repeats of a hexanucleotide sequence. The LBD is located
at the C-terminal region of NHRs and is responsible for hormone binding which, in turn, results in
a conformational change in the NHR structure. This conformational change affects the interaction
of various NHR cofactors, which can be classified as either coactivators or corepressors, and
functions together with the NHR to mediate changes in gene expression.
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Figure 1.5 Multi-dimensional representation of a standard NHR. Figure adapted from Fruchart
et al., 2019 providing the general structure of NHRs. The A/B, D, and F regions are variable while
the C and E regions are conserved through all classes of NHRs. Region A/B is the variable NTerminal, Region C is the DNA binding domain or DBD, Region D denotes the hinge region, E is
the ligand binding domain or LBD, and F is the variable C-terminal domain.
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Based on dimerization and DNA-binding properties, NHRs fit into one of four different
groups: steroid hormone receptors, repeat (RXR) and symmetrical repeat (LXR) binding receptors,
ligand-dependent receptors, and monomeric receptors that bind to core sites (Table 1.1)
(Mangelsdorf et al., 1995). All of these NHRs share certain common structures and functional
domains, but they differ in how and where they bind to target HRE sequences based on variations
occurring in the N-terminal region, C-terminal region, and hinge region. For instance, steroid
receptors (Type 1) typically bind ligands in the cytoplasm before being actively transported into
the nucleus, while RXR heterodimers (Type 2) remain in the nucleus at all times. Both steroid
receptors (Type 1) and dimeric orphan receptors (Type 3) bind HREs with sequence specific
binding recognition half-sites, but Type 1 binds to inverted HREs that are separated by a variable
region, and Type 3 binds to HREs that are direct repeats. Unlike Types 1, 2, and 3, Type 4 NHRs
bind to only a single half-site HRE on the target gene (Klinge, 1997). Most orphan nuclear
hormone receptors fall into either the dimeric or monomeric categories.
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Table 1.1 The four subclasses of nuclear hormone receptors. Adapted from Mangelsdorf et al.,
1995, each class of NHR is identified by the variable region based on dimerization and DNAbinding properties. The regions labeled with question marks represent orphan segments where the
ligands remain unknown.
Dimerization

HRE Binding

Examples

Homodimer

Inverted specific
half-sites

Glucocorticoid Receptor,
Progesterone Receptor,
Androgen Receptor, Estrogen
Receptor

Type 2:
Heterodimers with
RXR

Heterodimer

Repeat, half-sites
separated by a
variable region

Thyroid Hormone Receptor,
Eicosanoid Receptor

Type 3: Dimeric
Orphan Receptors

Homodimer

Direct repeat halfsites

Retinoid X Receptor

Type 4:
Monomeric Orphan
Receptors

Monomer

Single, half sites

DAX-1 Receptor

Type 1: Steroid
Receptors
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Critically, nuclear hormone receptors play complex roles in cancer progression and
tumorigenesis. One such example of the complexity of NHRs in cancer is the repression of thyroid
hormone nuclear receptors (TRs) that mediate the growth, differentiation, and metabolic functions
that are promoted by thyroid hormone. Studied in breast and colon cancer, TR is expressed in low
quantities and due to crosstalk with the tumor suppressor protein p53, TR cannot function as a
gene activator and regulator of cancer cell growth (Bhat et al., 1997). Other studies have
highlighted the importance of NHRs as drug targets for cancer treatment. Specifically, the
expression of orphan nuclear hormone receptors in the subfamily NR4A1/NUr77/NGFIB have
been implicated in the progression of cervical cancer. Research suggests that these NHRs are
affiliated with the survival of cervical cancer cells and that the downregulation of gene expression
of NR4A2 may suppress cancer progression (Ke et al., 2004). Alternatively, the NR4A nuclear
receptor family serves as tumor suppressors in Acute Myeloid Leukemia (AML) where oncogenic
promoting pathways are aberrantly activated and overexpressed (Call et al., 2020). Other tumor
suppressors such as the Nuclear Receptor Subfamily 0, Group B Member 2 (NR0B2), also referred
to as the small heterodimer partner, SHP, are epigenetically silenced via hypermethylation in the
promoter region in hepatocellular carcinoma (He et al., 2008). Thus, expression of nuclear
receptors have increasingly become possible therapeutic targets for cancer treatment (Call et al.,
2020). This further gives rise to the possibility that expression of the gene of interest for this thesis,
DAX-1, may have oncogenic correlations.
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DAX 1/NR0B1
The gene and nuclear hormone receptor DAX-1, is the focus of the experiments outlined
in this thesis. As previously described, most nuclear receptors bind directly to HRE sequences in
the promoter regions of target genes. However, orphan nuclear receptors, including DAX-1, lack
a ligand binding domain (LBD) yet can still mediate functions such as dimerization and coactivator
interactions. DAX-1 specifically belongs to the subfamily of orphan hormone nuclear receptors. It
is identified as an orphan because, unlike the steroid and non-steroid hormone receptors, DAX-1
has not been shown to bind to a specific ligand. As its name implies, multiple copies of the DAX1 gene region on the X chromosome are associated with male to female sex reversal in human
development (Dosage Sensitive Sex Reversal, or DSS). The role of DAX-1 in this context is as a
negative regulator of estrogen, progesterone, and androgen receptors and therefore, antagonizes
testicular development through inhibition of gene expression (Iyer & McCabe, 2004). More
generally, DAX-1 is characterized as a repressor of gene expression activated by ligand-induced
transcriptional activation (Lalli, 2014; Lalli et al., 1997). DAX-1 suppresses steroidogenesis in
adrenal cells by binding to hairpin DNA structures. However, the function of DAX-1 goes beyond
suppression; the unique structure of this NHR allows for transcriptional silencing. DAX-1 serves
as a form of tumor assessor in prostate cancer and pituitary adenomas as well as an indirect tool
for measuring androgen receptor expression in breast cancer and estrogen receptor expression in
endometrial carcinoma (Lalli, 2014).
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As an orphan receptor, DAX-1 does not follow the typical NHR structure. Instead, DAX1 lacks the modulator and hinge regions as well as the conserved zinc finger DNA binding domain
(Figure 1.6). Intriguingly, DAX-1 has three times as many leucine rich LXXLL repeats than are
commonly found in coactivator proteins that are important in mediating binding to ligand induced,
AF-2 (Activating Function 2) domains on other NHRs (Lalli, 2014; Zanaria et al., 1994). The
complex formed by the LXXLL motif and the LBD can then recruit the silencing domain in the
DAX-1 C-terminus leading to transcriptional silencing (Lalli, 2014).

32

Figure 1.6 Structure of the DAX-1 NHR compared to a typical NHR. Unlike other nuclear
receptors, DAX-1 does not have a modulator (A/B) or hinge region (D) and what would be the
DNA binding domain (DBD, region C) is missing the zinc finger region that is typical in other
nuclear hormone receptors. Instead, the DAX-1 DBD contains three leucine rich LXXLL repeats
that have been shown to mediate cofactor binding in other nuclear hormone receptors. The DAX1 protein consists of 470 total amino acids, with the N-terminal region spanning the first 253 amino
acids. The DBD is located in this region and includes 3 complete and one incomplete
Alanine/Glycine (A/G) rich repeats. Each of these A/G rich repeat regions contains 3 LXXLL-like
motifs.
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Orphan NHR’s can regulate gene expression and endocrine responses without binding to a
ligand. This process is referred to as the ligand independent pathway (Figure 1.7). In the absence
of a ligand, nuclear receptors work in conjunction with coregulators through protein-protein
interactions to recruit proteins such as RNA polymerase.
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Figure 1.7 Ligand independent binding nuclear hormone receptor pathway. Figure adapted
from Guo & Ren, 2013, highlights the mechanism of NHRs within the nucleus. In the absence of
a ligand, the NHR binds a corepressor that leads to transcriptional repression. Upon ligand binding,
the NHR releases the corepressor and binds a coactivator that allows for the recruitment of RNA
polymerase.
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Coregulators are classified as either coactivators or corepressors. Coactivators bind to the
ligand-dependent (or ligand activated) NHRs to increase target gene expression. Figure 1.8 shows
the activated Liver X Receptor (LXR) bound by a ligand which will form a heterodimer with
Retinoid X Receptor (RXR). Together, they are bound by a coactivator that recognizes target genes
(Zanaria et al., 1994). Conversely, corepressors bind to unliganded NHRs, resulting in a decrease
in gene expression.
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Figure 1.8 Mechanism of a Type 2 NHR binding with coactivator. Figure adapted from
Heskett, 2014; only one nuclear receptor of this heterodimer can bind a ligand, in the example
shown it is LXR. However, RXR recruits a coactivator to allow for dimerization and to induce
transcription.
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Thus, while the ligand binding domain (LBD) of an orphan NHR such as DAX-1 does not
bind to any specific ligand, it does have other functions. Namely, the LBD is important for receptor
dimerization and coactivator interactions. There are three pathways (Figure 1.9) that describe the
mechanisms by which DAX-1 can repress transcription during gene regulation: by binding the AF2 site of another NHR, by hijacking the coactivator binding domain in other NHRs, or by binding
directly to the promoter of single stranded DNA (Iyer & McCabe, 2004).
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Figure 1.9 The three ways in which DAX-1 can repress transcription. Adapted from Iyer &
McCabe, 2004, DAX-1 can silence gene expression via three pathways. A) DAX-1 hijacks an
activator (AR) and prevents it from entering into the nucleus. B) DAX-1 inhibits gene expression
by binding the AF-2 site of another NHR and works in conjunction with corepressors. C) DAX-1
can also bind directly to the promoter region of single stranded DNA of target genes and inhibit
transcription.
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Previous research has shown that NHRs regulate a wide-range of normal biological
processes, including embryonic development and sex determination (Lalli, 2014). In embryonic
stem cells, orphan NHRs, specifically LRH-1, DAX-1, and SF-1, work together with a complex
of proteins to maintain pluripotency. DAX-1, in particular, functions to maintain totipotency in
embryonic stem cells and was first associated with X-linked adrenal hypoplasia congenita (AHC)
and dosage sensitive sex reversal (DSS) in these cells (Lalli et al., 1997; McCabe, 2007). In DSS,
mutations on the X chromosome result in sex reversal due to a duplication in the region containing
the DAX-1 gene (Lalli, 2014). When expressed in the hypothalamus and pituitary, mutations in
DAX-1 are responsible for most cases of cytomegalic AHC and may also cause hypogonadotropic
hypogonadism (HHG) (McCabe, 2007). AHC specifically is the result of mutations in the DAX-1
gene that cause diminished development of adrenal tissue, leading to a reduction in adrenal
hormone production (Lalli et al., 1997). Since this initial discovery of DAX-1 function, DAX-1
has quickly become a topic of scientific interest because of its presence in all regions of the
hypothalamic-pituitary-adrenal-gonadal (HPAG) axis during development and in adult tissues.
NHRs have been shown to play important roles in abnormal physiological processes,
including tumor cell initiation and cancer progression. Previous studies by our lab and others have
shown DAX-1 is expressed in different breast and prostate cancer cell lines, however, expression
levels vary widely (Boitano, 2009; Heskett, 2014). Our lab has found that DAX-1 functions, in
general, as a repressor of cancer cell growth. While the potential correlative effects of DAX-1 and
cancer have been studied in breast, prostate, lung, adrenal, and liver cancer, the precise mechanism
of this action is not well understood. In order to better understand the role of DAX-1 not only in
regulating cancer cell growth, but also in normal physiological functions, it is essential to
determine what factors are directly responsible for controlling its expression (Conde et al., 2004;
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He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al., 2018; Kumata et al., 2018).
We hypothesize that the DAX-1 gene is epigenetically regulated, specifically via methylation,
in cancer cells, thereby reducing its expression. Differences in the methylation of CpG islands
located near the DAX-1 promoter result in the variation of DAX-1 expression in different
human cell lines. To investigate this hypothesis, a broad assessment of the promoter region of the
DAX-1 gene was initially performed. Initial experiments explored DAX-1 expression at the RNA
and protein levels. These results were then followed by assays broadly identifying degrees of
methylation of CpG islands. Most DNA methylation occurs at CpG islands where there is a high
concentration of CpG dinucleotides and can suppress the expression of nearby genes
(Manoochehri et al., 2016). Within the promoter region of the human DAX-1 gene, there are nine
CpG islands of CCGG sequence (Figure 1.10).
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Figure 1.10 Promoter region of Exon 1 of the DAX-1 gene. Highlighted in red is the
transcriptional start site. Each region highlighted in yellow is a CCGG CpG island that may be a
target of cytosine methylation.
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Following this initial analysis, the focus of this project was refined to investigate three cell
lines: one cancerous cell line with a high degree of methylation, one cancerous cell line with a low
degree of methylation, and one non-cancerous control cell line. Within these three cell lines,
sequence analysis of bisulfite modified gDNA was utilized to more accurately assess the degree
of methylation in a region of interest. Finally, the mechanism of DNA methylation in these cell
lines through the use of chromatin immunoprecipitation (ChIP) assays was investigated in order
to hone in on the different methylating protein occupancy between cancerous and non-cancerous
breast cells. Through the following experiments, a better understanding of the factors that control
DAX-1 expression in a variety of human cell lines was obtained. The contribution of these results
will provide a deeper understanding as to how DAX-1 expression may be controlled in human
disease and may lead to the development of more efficacious and targeted therapies in the future.
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Chapter 2: Determination of the level of DAX-1 expression across different
human cell lines
Introduction
Previous research in the Tzagarakis-Foster lab has shown that the DAX-1 promoter region
and exon 1 contain CpG islands that can be methylated (Dishington, 2017; Heskett, 2014; Judge,
2011). These earlier experiments examined only a few cell lines for DAX-1 expression and
methylation status. Thus, the first specific aim of this thesis research was to determine the level of
DAX-1 expression across cancerous and noncancerous human cells using various molecular
techniques including polymerase chain reaction (PCR), quantitative PCR (qPCR), western blot,
and restriction digestion analysis.
Each of the cell lines examined were selected for their association with DAX-1 or other
nuclear hormone receptors based on previous research in the Tzagarakis-Foster lab or literature
reviews (Conde et al., 2004; He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al.,
2018; Kumata et al., 2018). Amongst the cell lines not previously investigated by the TzagarakisFoster lab but included in this research are those derived from cervical and hepatocellular cancer.
In 2018, cervical cancer was the fourth most lethal form of cancer in women worldwide. Studies
have found that the DAX-1 protein is upregulated in cervical cancer and when silenced,
tumorigenicity is inhibited (Liu et al., 2018). Furthermore, DAX-1 has been shown to
transcriptionally repress genes that regulate oncogenic gene expression downstream. Most of the
cell lines included in this study (e.g. testes, ovaries and breast) are associated with sex steroid
synthesis. The exception to this is the Hep-3B cell line, which is isolated from a hepatocellular
carcinoma. Previous findings immunolocalized synthesized sex steroids and hormone receptors,
including DAX-1, in the mucous epithelial cells of neoplasms on the liver (Kumata et al., 2018).
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Examination of DAX-1 expression in liver cells was included in this study to provide a comparison
against the steroid hormone producing tissues previously investigated in the Tzagarakis-Foster
lab.
Ultimately, experiments confirmed the detection of DAX-1 in the genome of the cancerous
and control cell lines. Following successful detection of DAX-1 at the genome level, RNA and
protein level analyses confirmed differential expression of DAX-1 within the cancer cell lines.
General analysis of methylation status was assessed with methylation specific restriction enzyme
assays. The restriction enzyme analysis highlighted the diverse levels of methylation across the
promoter region, indicating a correlation between increased methylation and decreased DAX-1
expression.
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Materials and Methods
Tissue Culture
Cell lines, obtained from American Type Culture Collection, were cultured according to
the recommended guidelines (ATCC Cell Lines, n.d.). Antimycotic and antibiotics were added to
the media to prevent bacterial and fungal infection of the lines. Multiple cancer cells lines were
analyzed for the differential expression and varying degrees of hypermethylation of the DAX-1
gene. The MCF10A cell line is derived from an immortalized breast tissue and serves as a noncancerous control. While MCF10A cells are non-cancerous and not derived from a tumor, they are
not considered ‘normal’. The MCF10A cells originate from a tissue sample of a patient with
fibrocystic disease and were immortalized through consistent passaging of the cells in a low
calcium media. In addition to this control cell line, five cancerous cell lines (Table 2.1) were
analyzed for DAX-1 expression. Each cell line was chosen based on prior investigation by the
Tzagarakis-Foster lab or the association that each particular cancer has with nuclear hormone
receptors such as DAX-1. Previous work in the Tzagarakis-Foster lab has shown that DAX-1 is
expressed in varying degrees within breast, lung, and adrenal cancer cell lines. In addition to these
cell lines, cervical adenocarcinoma cells and liver cells, shown to express DAX-1, were also
assessed (Kumata et al., 2018; Liu et al., 2018). MCF7 cells are human epithelial cells from a
female with breast cancer (adenocarcinoma) and express estrogen receptors alpha and beta and are
responsive to estrogen hormones. Human lung cancer cells, A549 cells, were taken from an adult
male with carcinoma. SW13 cells are derived from a female with grade IV carcinoma in the adrenal
gland/cortex. Hep-3B cells are isolated from tissue samples of a child with hepatocellular
carcinoma.
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Table 2.1 Cell lines used to investigate DAX-1 expression.

MCF7

Metastatic (pleural effusion) mammary gland, breast
cancer

A549

Lung, Carcinoma

HeLa

Cervical adenocarcinoma

SW13

Carcinoma, adrenal gland/cortex

Hep-3B

Liver, hepatocellular carcinoma

MCF10A

Mammary gland/breast, fibrocystic disease
(immortalized)
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PCR
Standard polymerase chain reaction (PCR) was performed to confirm the presence of DAX1 in each cell line. Genomic DNA (gDNA) was isolated from cultures grown in T75 tissue culture
flasks using the PureLink® Genomic DNA Mini Kit (Invitrogen, Life Technologies, catalog #
K1820-02). Following gDNA isolation, samples were quantified using a Nanodrop
spectrophotometer and each sample was normalized to 150ng per μL. Genomic DNA samples
were analyzed for DAX-1 genomic detection using PCR. Samples were prepared using GoTaq 2x
Master Mix (Promega), and primers were designed to two different regions of the X chromosome
region containing the DAX-1 gene region. The first primer set amplified a region spanning from
Exon 1 into Intron 1, and the second targeted a region entirely within the first intron. Targeting
these regions ensured that amplified products were generated from genomic DNA as opposed to
mRNA. PCR conditions and primers (Tables A.1 and A.2; Appendix A) obtained from Integrated
DNA Technologies were optimized over multiple trials.
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qPCR
In order to assess DAX-1 mRNA expression in the cell lines, quantitative PCR, or qPCR,
was utilized. qPCR, as opposed to “end-point” PCR, combines the amplification and detection
steps and allows for quick and highly accurate data collection. Furthermore, the process is highly
sensitive compared to alternative methods, and can detect differential gene expression more
precisely between samples with lower degrees of variation (M. L. Wong & Medrano, 2005).
Confluent cells were isolated from T75 tissue culture flasks and total RNA was isolated using the
Monarch® Total RNA Miniprep Kit from New England Biolabs® Inc. (Product # T2010S).
Following RNA isolation and quantification using a Nanodrop spectrophotometer, cDNA was
synthesized using Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Fisher, Product #
K1651). qPCR reactions were prepared using PerfeCTa® SYBR® Green Fast Mix® from
QuantaBio (Cat. # 95072-250, -012, -05K). SYBR green exhibits very little fluorescence when it
is free in solution, but the fluorescent signal increases substantially when it binds non-specifically
to double stranded DNA. cDNA samples were amplified using primers directed to the DAX-1 gene.
Primer and qPCR parameters (Tables A.1 and A.2; Appendix A) were used to isolate a region of
the DAX-1 gene that was not removed during RNA splicing.
The first means of assessing DAX-1 RNA expression utilized the standard curve method
(Qiagen, n.d.). In this approach, a set of serial dilutions was prepared from a DNA template of
known concentration. These samples were used to obtain a standard curve that was used for the
relative quantification of unknown samples. The DNA template used to prepare a standard curve
was generated from the same DAX-1 amplicon that was generated using a DAX-1 plasmid. The
amplified DAX-1 plasmid DNA was prepared with the Wizard® SV Gel and PCR Clean-Up
System (Product # A9281, Promega). Amplification and analysis was performed using the BioRad
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CFX-96 system. Utilizing this plasmid as a control allowed for direct quantitative comparison of
DAX-1 expression in the experimental cell lines. Data was collected in sets of three technical
replicates per biological sample and over a minimum of three biological replicates. The standard
deviation corresponds with the triplicate samples analyzed on a single 96-well plate and was
calculated in Microsoft Excel with the following equation (Microsoft, n.d.):
!"#$%#&% ()*+#"+,$ = !.(/0 = 1

∑(#! $#"#$ )%
(&$')

; Where xi is a single value, xave is the mean of

the sample set, and n is the number of samples.

In addition to utilizing a standard curve of DAX-1 plasmid for comparison described
above, a second means of analysis was also implemented. In this approach, each of the cancerous
cell lines was normalized against the control cell line to compare relative DAX-1 expression in
cancerous versus noncancerous cells. The normalization was calculated based on the Cq value (the
number of amplification cycles) with the following equation:
2$∆)& , where ∆4* = 4* ,-./01 − 4* 23&4530 , or ∆4* = 4* 2-&21536, − 4* 7)8'9:

The following equation was used to calculate the standard error of the two means from the
normalized cell lines against the noncancerous MCF10A cells (Comparison of Means Calculator,
2021):
(&' $'),' % ; (&% $'),% %

!"#$%#&% /&&,& = 1

(&' ; &% )$<

; where n1 is a single Cq sample, n2 is a single Cq MCF10A,

s1 is the standard deviation between the sample replicates, s2 is the standard deviation between
the MCF10A replicates, and n is the number of technical replicates of each sample respectively.
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Protein Isolation and Western Blot Analysis
Total protein lysate from confluent 10 cm tissue culture dishes was collected using the Cell
Extraction Buffer kit (Invitrogen, Life Technologies, Ref# FNN0011) and Halt™ Protease
Inhibitor Single-Use Cocktail (1000X) from Thermo Scientific (Ref #1860932). Protein lysates
were quantified using a Bradford protein assay. Pre-Diluted Protein Assay Standards: Bovine
Albumin (BSA) set from Thermo Scientific (Prod. #23208) were used to generate a standard curve,
and samples and standards were prepared using the Bio-Rad Protein Assay Dye Reagent
Concentrate (5x) from Bio Rad (Cat. #5000006). All samples were measured via spectroscopy.
Western blot analysis was carried out according to the NuPAGE Novex Bis-Tris protocol
(Invitrogen, Carlsbad, CA). 10µg of each isolated protein sample was added to NuPAGE LDS
sample loading buffer (1X final concentration), NuPAGE reducing agent (1X final concentration)
and nuclease free water to a total volume of 20μl. 5µL of a 10-20% Tris-glycine Gel Ladder from
Protein Tech was loaded into one lane for sample analysis after imaging. Samples were
electrophoresed using the XCell II Blot Module (Invitrogen, Carlsbad, CA) at 200V for 60
minutes. Proteins were transferred to PVDF membranes using the XCell II Blot Module apparatus.
Following transfer, PVDF membranes were washed three times in 1X TBST for 10 minutes per
wash at room temperature. Membranes were blocked in 5% milk in 1X TBST for 1 hour at room
temperature. Primary antibodies (DAX-1: Invitrogen anti-rabbit, GAPDH: GeneTex anti-mouse)
were diluted 1:1000 in 5% milk in 1X TBST, and added to blots to incubate overnight on a rotator
at 4˚C. This antibody was selected following a survey of anti-DAX-1 antibodies (Figure 2.1).
Following overnight incubation, blots were washed three times for ten minutes in 1X TBST and
incubated for 60 minutes at room temperature in secondary antibody diluted 1:2000 (GeneTex
anti-rabbit, BD Pharmingen anti-mouse) in 5% milk in 1X TBST. PVDF membranes were washed
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three times for 10 minutes in 1X TBST. In order to detect protein-antibody complexes,
chemiluminescent SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific
REF 34095) was added to each membrane and incubated according to the manufacturer’s
recommendation. Membranes were exposed and images captured using the GelDoc Imager and
camera system (BioRad, Hercules, CA).
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Figure 2.1 Optimization of primary antibody selection for assessing DAX-1 protein
expression. While faint ‘on-target’ bands are visible at 50kDa indicating antibody binding the
DAX-1 in lanes 1-4, maximum signal was detected with the primary anti-DAX-1 antibody for
Invitrogen (Lane 4). Protein size is denoted with YesBlotTM Western Marker 1 (SmoBio, Product
#WM1000).

53

Methylation Specific Restriction Enzyme Analysis and PCR
For each cell line, genomic DNA was isolated and used for methylation specific restriction
enzyme digestion and analysis. Genomic DNA (gDNA) was isolated through the same technique
described previously. The gDNA samples were digested using methylation-sensitive restriction
enzyme HpaII and its isoschizomer MspI, which has the same recognition site but is methylation
insensitive (New England BioLabs, Inc.). A fragment was designated ‘unmethylated’ if no PCR
product was observed after digestion; alternatively, the fragment was designated ‘methylated’ if it
was amplified after digestion (Melnikov, 2005; Salmon et al., 2008; Yang et al., 2011). Together,
these enzymes can differentiate methylation status of CCGG dinucleotide sequences (Figure 2.2).

54

Figure 2.2 Methylation status sensitivity to enzymes HpaII and MspI. Figure adapted from Fu
et al., 2012, these enzymes target CCGG CpG islands and ‘cut’ depending on the location of the
methyl group. These enzymes have a sensitivity to CCGG methylation status and can determine
the location of methylation through a restriction digest of the gDNA when primed to target the
promoter region of DAX-1. The addition of a methyl group (CH3) protects against enzyme
digestion. Therefore, regions marked as ‘cut’ are unprotected and regions marked as ‘not cut’ are
protected via methylation (Salmon et al., 2008; Yang et al., 2011).
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Both of these enzymes target CpG islands, specifically those of CCGG sequence. Reactions
containing enzyme, specific buffer, and gDNA were incubated at 37˚C for 2 hours. This method,
while limited in that it is only a very crude examination of methylation status, can be used to
quickly assess the methylation status of the DAX-1 genomic region in the cell lines described
previously. When compared alongside control gDNA, the intensity of products was used to
determine whether a CpG-rich region was either hemi-methylated or methylated, unmethylated,
or fully methylated. Both the gel image product and the corresponding band intensity were used
to categorize CpG islands into one of these three degrees of methylation. A region and its
respective CpG island(s) were marked as hemi-methylated or methylated if the product in the
HpaII lane was of similar intensity as the undigested control, or if the HpaII and MspI lanes both
showed relatively similar products to each other and the control. Alternatively, a region of CpG
island(s) was considered methylated following MSRE if the product of the HpaII digest was more
intense than the control or if it was less than the control and there was negligible product following
digestion by MspI. Finally, a region and the associated CpG island(s) was deemed unmethylated
if there was little to no PCR amplified product following both HpaII and MspI digestion.
Following the restriction digest with HpaII or MspI enzymes, DNA was purified (Monarch
PCR DNA cleanup kit, New England Biolabs, Inc.) and used as template for standard PCR
reactions. CpG islands targeted by HpaII/MspI enzymes were located on the NR0B1/DAX-1
sequence using the Li Lab MethPrimer software (L. C. Li & Dahiya, 2002). This software
identifies CpG-rich regions containing high densities of CG or CCGG sequences (Figure 2.3).
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Figure 2.3 CpG rich regions of the DAX-1 promoter. CpG rich regions were identified and
compiled using the Meth Primer tool for the Li Lab (L. C. Li & Dahiya, 2002). The transcriptional
start site and TATA box are located at the end of Region A, located at approximately 240 base
pairs.
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Having identified CpG-rich regions, primers for the PCR reactions were designed using
Primer3 software v0.4.0 (Kõressaar et al., 2018; Koressaar & Remm, 2007; Untergasser et al.,
2012), so that primers would flank the HpaII/MspI enzyme cutting site (5′-CCGG-3′) in the
sequences. Particular attention was given to designing these primers, breaking the CpG-rich region
of the DAX-1 promoter into five sub-regions that each contained at least one CCGG sequence
(Figure 2.3). Furthermore, the primers were developed such that melting temperatures were
relatively similar with 5-10˚C difference between primer sets (Table A.2; Appendix A). In an
effort to use these primers in tandem with the digested gDNA, some of the amplified regions
overlap and encompass the same CpG islands (Figure 2.4). Region A isolated one CpG island and
Region B encompassed three unique CpG islands. Regions C and D overlapped, each including 1
unique CpG island, and Region E targeted one CpG island. While MSRE provided a crude
assessment of methylation status, minimizing the number of CpG islands targeted within each PCR
region allowed for increased specificity in the location of methylation.
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Figure 2.4 The DNA sequence of DAX-1 promoter region with MSRE primers. Five different
primer sets are shown, each amplifying a different CpG island. Forward and reverse primers are
highlighted along with the CpG islands the amplified region encompasses. Primer design Region
A is yellow, Region B is blue, Region C is purple and overlaps with Region D in pink, Region E
is in green.
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All PCR reactions were performed using Promega GoTaq Green Master Mix (catalog #
M7121) (Table A.1; Appendix A). Endpoint PCR products were separated by electrophoresis
through a 2% agarose gel with ethidium bromide and visualized using the BioRad Gel Doc Imager.
Only products that had not been digested by the enzyme could be amplified via PCR, resulting in
a product visible on the agarose gel. Quantitative values were derived from band intensity via
densitometry using the ImageLab software associated with the gel doc (Image Lab Software | Life
Science Research | Bio-Rad, n.d.).
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Results
gDNA DAX-1 Detection
The initial confirmational assay was crucial to determining that DAX-1 is present within
the cancerous and immortalized cell lines. Cancer frequently involves mutagenesis, often resulting
in chromosomal aberrations (Chinnaiyan & Palanisamy, 2010). Since the DAX-1 gene is found on
the X chromosome, determining that a potential chromosomal aberration had not disrupted this
target gene was critical prior to assessing RNA and protein level expression of DAX-1. To check
this, DAX-1 genomic level detection was assessed with standard PCR and the products were
visualized using gel electrophoresis. As shown in Figure 2.5, PCR products of the appropriate size
in all cell lines assayed, confirm the DAX-1 gene is intact and mutation in these cell lines has not
compromised the target gene. Though not shown in triplicate, these results are consistent with
multiple repetitions.
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Figure 2.5 Detection of DAX-1 in the genome. Amplification of two distinct regions of the
genome containing the DAX-1 gene followed by gel electrophoresis is shown. Six different cell
lines were analyzed: MCF10A non-cancerous immortalized breast cells, A549 lung carcinoma,
HeLa cervical cancer, Hep-3B liver carcinoma, MCF7 breast cancer, and SW13 adrenal cancer.
The control cell line is indicated in blue, while the cancerous cell lines are denoted by orange
highlighting.
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DAX-1 RNA Level Expression
Quantitative PCR (qPCR) was utilized to measure the level of DAX-1 gene expression in
each cell line. For these experiments, two quantification methods were employed. In the first
approach, a standard curve was generated using known input amounts generated from PCR
amplification using a DAX-1 expressing plasmid as the DNA template. In the standard curve
method, a range of known concentrations of DAX-1 plasmid were used to derive quantitative
comparisons of RNA level expression. Beginning at 1ng/µL and decreasing to a low concentration
of 0.1pg/µL, the number of amplification cycles needed to detect DAX-1 in the plasmid increases
as concentration decreases. By comparing the resulting Cq value (the number of amplification
cycles) derived from the standard curve to the Cq values of the experimental samples, relative
levels of DAX-1 expression in the cancerous and noncancerous cell lines was determined (Figure
2.6). In this quantification method, the higher Cq value indicates an increased amount of qPCR
cycles required to detect DAX-1. Thus, the larger the Cq, the lower the level of DAX-1 expression.
Based on this method of mRNA expression analysis, the highest level of DAX-1 expression is
observed in the A549 lung carcinoma cell line. This high level of expression is followed closely
by the SW13 adrenal carcinoma cancer cell line. In contrast, it took much longer for the qPCR to
detect DAX-1 RNA expression in the MCF7 breast cancer cell lines. Alternatively, DAX-1
expression in HeLa and Hep-3B (cervical and hepatocellular carcinoma), was between 1pg/µL and
0.1pg/µL, slightly higher than that detected in the MCF7 cell line. The DAX-1 RNA expression in
the MCF10A control cell line was also relatively low. This was to be expected as breast cells are
not major producers of DAX-1 such as adrenal cells that require DAX-1 to regulate steroid
hormone production (Dishington, 2017; Scandurra, 2014).
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Figure 2.6 Quantitative assessment of the DAX-1 RNA level expression compared to a
standard curve developed from the DAX-1 plasmid at varying concentrations. The standard
curve generated from the DAX-1 plasmid superimposed over the average Cq levels of each tested
cell line.
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In a more qualitative approach comparing relative DAX-1 expression levels in the
cancerous cell lines to the control, the differences in expression is striking (Figure 2.7). When
compared to the MCF10A non-cancerous control cell line, it is evident that the A549 lung
carcinoma and SW13 adrenal carcinoma have substantially higher levels of DAX-1 expression
than the Hep-3B hepatocellular carcinoma, the HeLa cervical carcinoma, or the MCF7 breast
cancer cell lines. Notably, the MCF7 breast cancer cells show the lowest RNA level expression of
DAX-1.
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Figure 2.7 Fold ‘Relative’ Expression of DAX-1. Each cancerous cell line was normalized
against the control, non-cancerous cell line for relative DAX-1 RNA level expression. A549 and
SW13 cell lines exhibit the highest level of DAX-1 mRNA expression and MCF7 cells exhibit the
lowest.
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DAX-1 Protein Level Expression
Western Blot analysis, that was used to determine the qualitative level of DAX-1 gene
expression at the protein level paralleled what was observed at the mRNA level. Protein expression
was compared to that of GAPDH, a housekeeping gene that is constitutively expressed in all cells
but may vary slightly amongst different cell types. Expression levels were based on the intensity
of the product band during chemiluminescent imaging. Similar to the RNA level experiments, the
western blot results confirm differential expression of DAX-1 across the cell lines (Figure 2.8). In
line with what was observed at the RNA level, lung (A549) and adrenal (SW13) carcinomas
demonstrated the highest DAX-1 protein expression while the breast cancer cell line (MCF7) had
low expression. The hepatocellular carcinoma (Hep-3B) cells gave protein expression results
consistent with those obtained from the RNA level analyses, categorizing them as low expressors
of DAX-1 in both experiments but having slightly higher expression than that of the MCF7 cell
line. However, some variation is observed when analyzing the qualitative results of the western
blot compared to what was observed through qPCR. While the MCF10A control cells were average
expressors of DAX-1 mRNA, a protein product is not detected in the western blot. This could
indicate a translational mutation in which the DAX-1 RNA is not fully converted to protein or some
other mechanism of translational control that does not align with transcriptional control in this cell
line. In contrast, the cervical carcinoma (HeLa) cells are high expressors of DAX-1 at the protein
level but not at the mRNA level.
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Figure 2.8 DAX-1 protein expression assessed via western blot. The control cell line is labeled
in blue and cancerous cell lines are shown in orange. Red slash represents a cropped lane on the
image analysis.
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MSRE
Having observed differential DAX-1 expression at both the RNA and protein levels,
methylation specific restriction enzyme analysis provided a means to investigate the potential
correlation between methylation and expression. Using the isoschizomer enzyme pair HpaII and
MspI, the methylation status of the nine CCGG CpG islands in the DAX-1 promoter was crudely
assessed. A product should always be observed in the control, undigested sample. The gDNA
treated with HpaII enzyme will cut differentially based on the location and degree of methylation.
Finally, while the MspI enzyme should cut regardless of methylation status and therefore
theoretically never show a band, there are instances in which not all the gDNA was cut or it was
cut in a way that the primers could still anneal, resulting in some product amplification.
Beginning with Region A, containing one CCGG CpG island, there was considerable
variation in methylation status across the six cell lines (Figure 2.9). Based on the gel product
shown above the bar graph and the quantitative values indicated by the blue bars, the MCF10A
control cells are either methylated or hemi-methylated at this CpG island. In this case, the
categorization of either hemi-methylated or methylated results from a greater band intensity
following HpaII digestion, as well as some product following MspI digestion. Furthermore, both
digest products are comparable to the results of the control. Denoted in orange, the cancerous cell
lines can be assessed both qualitatively with the gel images or quantitatively with band intensity.
The DAX-1 gene in SW13 adrenal gland carcinoma, Hep-3B hepatocellular carcinoma, and MCF7
breast cancer cells are all hemi-methylated or methylated at this CpG island. This was determined
based on the relative intensity of bands following PCR amplification. The Hep-3B cells showed
some product following both digests, with the band intensity following HpaII digestion being
comparable to that of the control. Products from both digests are observed in the MCF7 cells as
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well, however with the SW13 cells it is more difficult to group this region into hemi-methylation
or methylation because of the intensity of the control when compared to either digest product. In
clear contrast however, the A549 lung carcinoma cells appear to be almost certainly unmethylated
at this region further upstream of the DAX-1 promoter with negligible results following the
restriction digest.

70

Figure 2.9 Methylation status of DAX-1 Region A as assayed by MSRE. Based on the PCR
product following HpaII and MspI digestion, the following crude assessments can be made of this
single CCGG CpG island: methylated or hemi-methylated in the control MCF10A cells;
unmethylated in the A549 lung carcinoma cells; methylated or hemi-methylated in the Hep-3B
hepatocellular carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells;
methylated or hemi-methylated in the MCF7 breast cancer cells; and methylated or hemimethylated in the SW13 adrenal gland carcinoma.
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The restriction digest results from the SW13 cell line in Region A highlight one of the
reasons why MSRE can only be used to crudely assess methylation status. Analysis of Region B
provides another example of why this technique is generally useful to begin honing in on areas of
interest in the DAX-1 gene, but cannot be used for a precise determination of methylation status.
This region, following the transcriptional start site and TATA box, contains three CCGG CpG
islands that may all be methylated differently and the MSRE analysis can only indicate an overall
methylation status and cannot distinguish each CCGG CpG island independently (Figure 2.10).
The MCF10A noncancerous cells are either methylated or hemi-methylated in this region, as are
the MCF7 breast cancer cells. The Hep-3B hepatocellular cells are likely methylated, and the
SW13 adrenal carcinoma, A549 lung carcinoma, and HeLa cervical adenocarcinoma cell lines are
unmethylated.
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Figure 2.10 Methylation status of DAX-1 Region B as assayed by MSRE. Based on the PCR
product following HpaII and MspI digestion, the following crude assessments can be made of this
region that encompasses three CCGG CpG islands: methylated or hemi-methylated in the control
MCF10A cells; unmethylated in the A549 lung carcinoma cells; methylated in the Hep-3B
hepatocellular carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells;
methylated or hemi-methylated in the MCF7 breast cancer cells; and unmethylated in the SW13
adrenal gland carcinoma.
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Moving downstream, Region C contains one unique CCGG CpG island and two that are
also amplified in Region D. After analyzing the Region C patterns and comparing them to Regions
A and B, a trend amongst the cell lines emerges (Figure 2.11). Once again, the MCF10A
noncancerous cell line is methylated at this region of the DAX-1 promoter, as are the Hep-3B
hepatocellular carcinoma cells and the MCF7 breast cancer cells. In comparison, the lack of any
bands, even faint, in the A549 lung carcinoma, HeLa cervical adenocarcinoma, and SW13 adrenal
gland carcinoma indicates these CCGG CpG islands are unmethylated.
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Figure 2.11 Methylation status of DAX-1 Region C as assayed by MSRE. Based on the PCR
product following HpaII and MspI digestion, the following crude assessments can be made of this
single unique CCGG CpG island: methylated in the control MCF10A cells; unmethylated in the
A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular carcinoma cells;
unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the MCF7 breast cancer
cells; and unmethylated in the SW13 adrenal gland carcinoma.
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Methylation status of Region D continues to support the pattern that the six cell lines fall
into two categories: differential methylation across the DAX-1 promoter and little to no
methylation in the DAX-1 promoter. Within Region D, containing one unique CCGG CpG island
and two shared with Region C, the noncancerous cells, hepatocellular carcinoma cells, and breast
cancer cells are all methylated, while the lung, adrenal, and cervical carcinomas are unmethylated
(Figure 2.12).
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Figure 2.12 Methylation status of DAX-1 Region D as assayed by MSRE. Based on the PCR
product following HpaII and MspI digestion, the following crude assessments can be made of this
single unique CCGG CpG island: methylated in the control MCF10A cells; unmethylated in the
A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular carcinoma cells;
unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the MCF7 breast cancer
cells; and unmethylated in the SW13 adrenal gland carcinoma.
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Finally, when analyzing Region E, which contains one CCGG CpG island, the pattern of
differential methylation across the DAX-1 promoter or little to no methylation in the DAX-1
promoter amongst the cell lines is further substantiated (Figure 2.13). The intense bands from the
HpaII digest in the MCF10A, Hep-3B, and MCF7 cell lines indicated that all are likely methylated
at this CpG island. In contrast, the lack of a product indicates that the HpaII and MspI enzymes
were able to digest the gDNA. Therefore, the CpG island in Region E in the A549, HeLa, and
SW13 cell lines was not protected via methylation.
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Figure 2.13 Methylation status of DAX-1 Region E as assayed by MSRE. Based on the PCR
product following HpaII and MspI digestion, the following crude assessments can be made of this
single unique CCGG CpG island: methylated or hemi-methylated in the control MCF10A cells;
unmethylated in the A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular
carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the
MCF7 breast cancer cells; and unmethylated in the SW13 adrenal gland carcinoma.
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The pattern of hemi-methylated or methylated versus unmethylated throughout the DAX-1
promoter is increasingly evident following the MSRE analysis (Table 2.2). Overall, the A549 lung
carcinoma cells, HeLa cervical adenocarcinoma cells, and the SW13 adrenal gland carcinoma cells
exhibited the lowest degree of methylation in the DAX-1 promoter region. The remaining
cancerous cell lines, Hep-3B hepatocellular carcinoma and MCF7 breast cancer, were at least
hemi-methylated at each amplified region containing a minimum of one CCGG CpG island.
Surprisingly, the MCF10A control, noncancerous cell line was also consistently methylated or
hemi-methylated in the DAX-1 promoter region.
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Table 2.2. Summary of MSRE results grouped by cell line and amplified region of the
promoter. The MCF10A cell line is the control, non-cancerous cell line while the remaining cell
lines noted in orange are cancerous.
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Conclusion
The RNA and protein level analyses confirmed DAX-1 expression varies between the
different types of cancer cell lines analyzed. The highest level of DAX-1 expression at both the
RNA and protein levels was found in lung and adrenal carcinomas. Conversely the lowest
expression was detected in the metastatic breast cancer cell line. To further test the hypothesis that
expression may be decreased due to methylation of CpG islands, methylation specific restriction
enzyme analysis was used as a crude quantification of the degree of methylation of CpG islands
in the promoter region of the DAX-1 gene. Comparing these expression based results to the crude
assessment of methylation status of CpG islands within the promoter region, methylation is greater
in the cell lines that expressed low levels of DAX-1. Notably, the MCF7 breast cancer and Hep3B hepatocellular carcinomas were hemi-methylated or methylated at each amplified region
containing a minimum of 1 CCGG CpG island. Furthermore, amongst the cancerous cell lines the
highest expressor of DAX-1 at both RNA and protein levels was the A549 lung carcinoma and no
methylation was observed with MSRE analysis. The SW13 adrenal carcinoma was also a high
expressor of DAX-1 based on the qPCR and western blot experiments, but the methylation status
of the CpG island furthest upstream could not be determined with confidence with MSRE. The
two interesting outliers following the first set of experiments are the MCF10A noncancerous cells
and the HeLa cervical adenocarcinoma cells. Although the MCF10A showed average levels of
DAX-1 at the RNA level, at the protein level a product was barely visible. Furthermore, the MSRE
revealed the DAX-1 promoter is hemi-methylated or methylated throughout in the MCF10A
noncancerous cell line. This may be due to the irregular behavior and the role of DAX-1
occasionally observed mammary cells (Judge, 2011). While the cause of this variability is
unknown, it may be linked to cell growth conditions such as cell density. Indeed, it has been well
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documented that there is a heterogeneity and variability in the MCF7 cell line, although it continues
to be one of the most widely studied human breast cancer cell line (Lee et al., 2015, p. 7). In
contrast the HeLa cells expressed low levels of DAX-1 at the RNA level, but DAX-1 was
abundantly expressed at the protein level. This incongruity between DAX-1 expression levels in
RNA versus protein may be the result of translational regulation, where translation is not directly
related to transcription (Kelen et al., 2009). The RNA and protein data from the HeLa cancer cell
line aligned with the MSRE analysis results from the lung and adrenal carcinoma cell lines,
revealing a lack of methylation in each amplified region. This could indicate that an alternative
means of translational regulation is controlling DAX-1 expression in HeLa cervical
adenocarcinoma cells.
Ultimately, the results of these experiments confirmed that DAX-1 is differentially
expressed across multiple human cancer cell lines and that methylation patterns correlate with
some of this variation. These results also narrowed down which cell lines are likely exhibiting
regulation of DAX-1 expression via methylation as well as where the critical methylation site is
located in the promoter region. The first CpG island located nearest to the 5’ end of the promoter
region, and upstream from the transcriptional start site TATA box, was determined to be the most
critical island for further investigation. This evaluation was based on the results of the MSRE
analysis which demonstrated significant variation in methylation status across all six cell lines at
this CpG island, and was further supported by literature highlighting the importance of CpG islands
at the 5’ end of the promoter (Cross & Bird, 1995; Janitz & Janitz, 2011; Sleutels & Barlow, 2002)
Bisulfite sequencing was determined to be the best means to elucidate whether this CpG island is
protected via methylation in three cells line: A549 lung carcinoma – the highest expressor of the
DAX-1 at both RNA and protein levels with the least amount of methylation, MCF7 – the lowest
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expressor of DAX-1 that was methylated in the promoter, and MCF10A – the noncancerous cell
line. These results are presented and discussed in Chapter 3.
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Chapter 3: Identification of methylated CpG islands in the DAX-1 promoter
Introduction
The second aim of this project was to identify the CpG islands that are methylated in the
DAX-1 promoter. Specific focus was targeted on CCGG sequences surrounding the transcriptional
start site and TATA box. This aim was accomplished via bisulfite sequencing, where bisulfite
conversion and sequence analysis were carried out on the lung carcinoma cell line (A549), the
breast carcinoma cell line (MCF7), and the control (MCF10A), immortalized mammary gland cell
line. These three cell lines were selected based on the results of the DAX-1 expression and MSRE
analyses. The A549 cell line exhibited the highest RNA and protein level expression of DAX-1
and had the least amount of methylation in all five CpG rich regions in the promotor. Alternatively,
the MCF7 cell line consistently showed the lowest level DAX-1 expression and had one of the
highest degrees of methylation in all five regions of the promoter. The MCF10A cell line was
included as a control and counterpart to the breast cancer cells.
Bisulfite sequencing is the gold standard for determining the methylation status of gDNA
(L. C. Li & Dahiya, 2002; Wreczycka et al., 2017; Zymo Bisulfite Converted DNA Amplification
Guide, 2015). After gDNA is isolated, it is treated with sodium bisulfite, which deaminates
unmethylated cytosines to uracil. The converted UG regions are isolated using amplification and
directly sequenced with Sanger Sequencing (Figure 3.1). Bisulfite treatment does not deaminate
methylated cytosines, which are protected by methylation and remain as cytosines during DNA
sequencing. Therefore, the location of methylated cytosines is determined by comparing DNA
sequence analysis of bisulfite treated and untreated samples. By introducing site specific changes,
bisulfite treatment illuminates the methylation status of individual cytosine residues.
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Figure 3.1 Methodology of bisulfite conversion. Bisulfite sequencing allows for the precise
determination of methylation status in the genome. During bisulfite modification, unmethylated
cytosines are deaminated and converted to uracils. Therefore, after amplification and sequencing
the unmethylated cytosines will be denoted as thymine.
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In conjunction with results from bisulfite sequencing, chromatin immunoprecipitation
(ChIP) was utilized in order to build a model of methyl binding protein occupancy in the two
mammary cells lines. This approach was central to the identification of the methylating proteins
occupying the DAX-1 promoter region and to which CpG islands they are binding. There are two
primary families of proteins that directly interact with methylated DNA: DNA Methyltransferases
(DNMTs) and Methyl-CpG-Binding Proteins (MBPs) (L. Li et al., 2015).
DNMTs catalyze the transfer of a methyl group to 5’ cytosines. However, DNMTs are
essential to cell division and growth and therefore are a challenging target to use in narrowing
down methylation location via methylation modifying proteins. The second family, MBPs, are
composed of three sub-groups of proteins: Set and Ring Associated (SRA) domain proteins, Kaiso
and Kaiso-like proteins, and Methyl-CpG-Binding Domain proteins (MBD) (Sasai et al., 2010).
SRA domain proteins bind to methylated CpG islands and are observed in plants and
animals. However, they perform a diverse range of functions beyond methylation and have been
shown to bind methylated cytosines that are not part of CpG island in plants (Fournier et al., 2012).
Due to their diverse role and ability to bind any cytosine, this family of proteins is not as pertinent
to the investigation of specific CCGG CpG methylation.
The Kaiso and Kaiso-like family of proteins are an active field of research. First identified
as DNA-binding factors, these proteins can serve as transcriptional repressors when bound to
methylated CpG islands. Kaiso proteins are unique in their ability to also bind specific target
sequences (Fournier et al., 2012). However, Kaiso and Kaiso-like proteins can also bind to regions
not containing CpG islands, as well as regions containing a CpG island that cannot be methylated.
Due to their diverse occupancy, these are not a viable set of proteins for the aim of this project.
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Finally, Methyl-CpG binding proteins (MBP) or methyl-CpG binding domain proteins
(MBD proteins) are key regulators of repressed gene expression and recruit other epigenetic
regulators (Fournier et al., 2012; MBD1 Antibody (Clone 100B272.1), n.d., p. 1). Though this
protein family is large, consisting of eleven different proteins categorized further into three subgroups, the MBD sub-group of proteins have non-overlapping functions and bind to symmetrically
methylated CpG islands (Roloff et al., 2003). Furthermore, this protein family is known for their
role in epigenetic regulation and binding DNA with symmetrically methylated CpG islands
(Fournier et al., 2012; Hendrich & Tweedie, 2003; Roloff et al., 2003). Surveying various members
of the family illuminates their unique roles. MBD1 and MBD2 bind to methylated DNA, while
MBD3 does not (Fournier et al., 2012). Interestingly, while MBD1 occupies both methylated and
non-methylated regions and therefore should bind indiscriminately, it has an affinity for
unmethylated DNA (L. Li et al., 2015). MBD1 can also recruit other methylating proteins and
form a complex that methylates the DNA and represses transcription (L. Li et al., 2015). MBD2 is
a transcriptional repressor and along with HDAC, will package gDNA into inactive chromatin.
Therefore, areas in which MBD2 binds are likely regions in which DAX-1 is being repressed.
Finally, MBD3 forms a complex with HDAC in regions containing 5-hydroxymethyl cytosine
methylation. In addition to interacting with HDAC and colocalized DNMTs, when MBD2 and
MBD3 form dimerized complexes, they have an increased affinity to hemi-methylated DNA
regions (Tatematsu et al., 2000). The diverse roles each of these methylating proteins play in
epigenetic regulation and DNA binding can be utilized to clarify specific methylation status in the
promoter region of the DAX-1 gene (Figure 3.2).
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Figure 3.2 Summary of MBD proteins mechanism for repressing transcription. Adapted from
L. Li et al., 2015 and Liyanage et al., 2014, MBD1 and MBD2 bind to methylated promoters and
repress transcription. (TRD: transcription repression domain found with MBD1 and MBD2
repressed regions). MBD3 cannot bind to methylated regions, however, it can recruit other
epigenetic regulatory proteins, including HDAC and MBD2, to repress transcription.
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Materials and Methods
Bisulfite treatment
Thermo Scientific EpiJet Bisulfite Conversion Kit (REF: K1461) was used after literature
review revealed this kit is one of the premier bisulfite treatments available, preserving the integrity
of the gDNA more so than other commercially available kits (Brouwer, 2013; Darst et al., 2010;
L. C. Li & Dahiya, 2002; Schock & Traeger, 2011; Tierling et al., 2018; Worm Ørntoft et al.,
2017; Wreczycka et al., 2017; Zymo Bisulfite Converted DNA Amplification Guide, 2015).
Optimized results were achieved through Protocol A, the ‘long protocol’, as it had a higher DNA
conversion frequency (>99% versus >95%) and a lower degradation frequency. Modifying
reagents were added to purified and quantified gDNA. Following bisulfite conversion, the
modified gDNA was cleaned and desulphonated before amplification with PCR (Table A.1;
Appendix A).
Primers were designed with the recommended EpiDesigner bisulfite modified primer
software and were initially optimized using a temperature gradient for PCR, as well as minor
adjustments to the PCR protocol (EpiDesigner, 2017). The primers for bisulfite sequencing
amplified the region encompassing the first CCGG CpG island upstream from the TATA box
(Table A.2; Appendix A). A slightly larger region was amplified than previously seen in the
MSRE since sequencing often results in degraded base pairs at the beginning and end of the
sequence (Figure 3.3).
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Figure 3.3 The DNA sequence of DAX-1 promoter region with bisulfite primers. The primers
amplify the region nearest the transcriptional start site, specifically targeting the CpG island prior
to the TATA box.
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Bisulfite primers were first tested on a survey of gDNA to ensure optimized amplification
by PCR regardless of the timeframe in which the gDNA was isolated. Assessing the result of
bisulfite modification on previously isolated gDNA, gDNA taken from a preserved cell pellet, and
gDNA purified from recently lifted cells have similar relative levels of amplification (Figure 3.4).
However, the gDNA from the cell pellet gave the most robust amplification and therefore this
method of gDNA isolation was used as input for bisulfite modification.
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Figure 3.4 Comparison of source of gDNA used for bisulfite modification. Multiple bisulfite
primers were tested in A549 bisulfite converted gDNA to compare quality of PCR product
depending on different isolation sources. Shown in each set of six lanes are different primer sets
isolating various regions of the DAX-1 promoter that correspond with regions segmented for the
methylation specific restriction enzyme analyses. Water control samples (lanes 19-24) resulted in
a non-specific, primer-dimer product.
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Amplification via PCR was repeated for a total of three times, where the input for the
second and third rounds was 4µL of PCR product from the previous cycle. Following the third and
final PCR, 18µL of product was electrophoresed through a 2% agarose gel. The appropriately sized
PCR product was isolated from the gel, melted, and purified with the Wizard® SV Gel and PCR
Clean-Up System (REF: A9281, Promega). The resulting purified PCR product was cloned
directly into the pGEM T Easy plasmid (Promega) using the pGEM®-T Easy Vector System 1.
Following a 2 hour ligation at room temperature, the ligated product was transformed into
competent DH5a cells (One Shot®OmniMAX™, Invitrogen) and transformants were selected by
plating on LB agar plates containing ampicillin (100 µg/mL final concentration). After an
overnight incubation at 37˚C, 10 well isolated colonies were selected and transferred to LB
ampicillin liquid cultures to grow overnight at 37˚C with shaking at 250rpm. The following day,
plasmid DNA was purified from the bacterial cultures using the PureYield™ Plasmid Miniprep
System (Promega, REF A1222).
To confirm the correct product had been isolated and successfully cloned into pGEM-T
Easy, 5µL of the 25µL miniprep yield was used as input into a restriction digest reaction. Enzyme
volumes were between 0.3µL and 0.5µL per 10µL sample, with 1µL of corresponding NEB buffer,
and nuclease free water. Enzymes were chosen based on the pGEM-T Easy vector map (Figure
3.5). Restriction digest reactions were incubated overnight at 37˚C and analyzed the following day
by adding 2 µL Gel Loading Dye Purple (6x) (New England Biolabs #B7024S) prior to
electrophoresis of digested products on a 2% agarose gel.
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Figure 3.5 pGEM®-T Easy Vector map. Acquired from Promega pGEM®-T Easy Protocol
(Promega, 2018). Corresponding enzymes used for the restriction digest were selected from this
vector map to release the double stranded bisulfite modified DNA.
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Enzymes and corresponding buffers were utilized in the following restriction digest
reactions: Apa1 with Nde1 and Not1 with BstX1 (New England Biolabs, Inc). Only plasmids that
released a band corresponding to the PCR product size were submitted for DNA sequence analysis
(Molecular Cloning Laboratories) using M13 forward and reverse primers (Figure A.1). Control
sequences of non-bisulfite modified gDNA from each of the cell lines were sequenced using the
same amplification and isolation protocol to confirm DNA sequences match to known wildtype
DAX-1 sequences from NCBI.
Sequence products were analyzed manually and confirmed by Clustal Omega alignments
with SnapGene software (SnapGene | Software for Everyday Molecular Biology, n.d.).
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ChIP assays
Following the determination of differential methylation status of CpG islands in the DAX1 promoter, it was important to understand the mechanism of this epigenetic regulation.
Specifically, determining the identity of the methylating proteins that were likely mediating
changes in the methylation status of the DAX-1 gene was essential in order to elucidate the
mechanism. To address this, chromatin immunoprecipitation (ChIP) assays were carried out using
the MCF7 (breast cancer) and MCF10A (mammary gland immortalized) cell lines. ChIP assays
provide a means to isolate proteins that are physically bound to the CpG island sites in the DAX-1
promoter and exon 1, indicating their direct association with the DAX-1 epigenetic regulatory
region. Antibodies directed against known methylating proteins were used in the ChIP assays
allowing determination of whether a particular epigenetic regulatory protein is associated with the
DAX-1 promoter and/or exon 1 region. Subsequent PCR analysis allows for the correlation of
protein binding to a specific DNA region. ChIP can be used to specifically target methylating
proteins associated with the silencing of gene expression (Fuks et al., 2003; Viré et al., 2006). The
same primer sets utilized in Chapter 2 for the methylation specific restriction enzyme analysis were
also used in the ChIP assays.
ChIP assays were carried out using the ab500-ChIP kit (Abcam). Sonication of cross-linked
chromatin was performed by water bath sonication using a Misonix S-4000 sonicator in order to
fragment the chromatin into smaller pieces. The optimal size of sonicated chromatin should be
between 200 and 1000 base pairs. Sonication time was optimized by analyzing genomic DNA
fragment size after 5 minutes, 7 minutes, and 10 minutes of 30 second intervals. The resulting
DNA products were electrophoresed through a 2% agarose gel (Figure 3.6). Through these
experiments, it was determined that 7 minutes was the optimal sonication time.
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Figure 3.6 Comparison of different chromatin sonication times in the cancerous MCF7 and
control MCF10A cell lines. Alternating 30 seconds shear and 30 seconds off, optimized
chromatin product size was produced after 7 minutes of sonication. Ideal fragment size is between
200bp and 1000bp.
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Control ChIP reactions included non-crosslinked sheared chromatin samples that underwent
all other experimental conditions. Positive ChIP reactions included immunoprecipitations using
the HDAC antibody. Sheared chromatin that did not undergo further experimental conditions was
included as an “input” control. After sonication, sheared chromatin was diluted in buffer and 3µg
of the following antibodies were added for crosslinking:
● anti-MBD1 (methyl-CpG binding domain protein 1), rabbit polyclonal,
abCam (catalog # ab2846-100)
● anti-MBD2a (methyl-CpG binding domain protein 2), rabbit polyclonal,
abCam (catalog # ab3754-100)
● anti-MBD3 (methyl-CpG binding domain protein 3), rabbit polyclonal,
abCam (catalog # ab3755-100)
● anti-HDAC3 (histone deacetylase), rabbit polyclonal,
abCam (catalog # ab47237)

Reactions were incubated at 4˚C with rotation overnight prior to clean-up. A 50% slurry of
Protein A agarose beads was used to purify the antibody/chromatin product along with the
recommended number of wash steps. Maximum input of the final cross-linked and purified product
was used as a template for PCR amplification. Finally, reaction products were electrophoresed
through a 2% agarose gel stained with ethidium bromide. Based on the presence or absence of a
product following PCR amplification, a model of protein occupancy throughout the promoter
region was assessed.
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Results
Bisulfite Sequencing
Sequence analysis of control, non-bisulfite modified sequences aligned with NCBI NR0B1
gene sequence in the non-cancerous MCF10A breast cell line and lung carcinoma A549 cell line
(Figure 3.7). Although the MCF7 amplicon is consistent with the primers designed to segment the
region surrounding the TATA box and first CpG island, the results were not included alongside
the MCF10A and A549 initial alignment shown in Figure 3.7. Unfortunately, while the MCF7
breast cancer non-bisulfite modified product was still within the DAX-1 gene, the amplicon
showed a different sequence. Across multiple biological replicates with ten clones each, all
resulted in successful primer alignment and had the same amplicon region (Figure A.2; Appendix
A). This difference in MCF7 sequence results could be due to the previously discussed
heterogeneity and variability well documented by other researchers (Lee et al., 2015).
Furthermore, when entered into BLAST (NCBI BLAST, n.d.) these sequences matched the NR0B1
gene, confirming that we were analyzing the DAX-1 gene in MCF7 cells and could continue with
bisulfite analyses.
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Figure 3.7 Sequence alignment of DAX-1 promoter region. Sequence alignment comparison of
the control, non-bisulfite converted MCF10A and A549 cell lines to the NCBI sequence. The
clonal sequences tested had a high rate of similarity (Figures A.2, A.3, and A.4; Appendix A).
MCF7 data is not shown on this alignment due to slightly different amplicon falling between these
primers. The clonal alignments are shown in Figure A.2; Appendix A.
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In comparison, the bisulfite treated data was heavily degraded and was more challenging
to align. A crude alignment did show successful conversion of most cytosines to uracil (Figure
3.8). Within this region, each cytosine not protected by a methyl group was converted to a uracil,
reading as a thymine in the final DNA sequence analysis. This selected area demonstrates the
power of bisulfite conversion in unmethylated sequences. Furthermore, as this region is early in
the sequence, this data confirms each of the three cell lines were successfully bisulfite modified
and that the region being amplified is on target.
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Figure 3.8 Sequence alignment of deaminated cytosines in DAX-1 promoter region of
bisulfite modified DNA. Highlighting the successful alignment and conversion of unmethylated
cytosine into uracil, which translates to thymine during sequencing.
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Highlighting a second region in the bisulfite modified sequence that follows the CCGG
CpG island and TATA box demonstrates the protection of certain cytosines (Figure 3.9). Cytosine
methylation can occur at non CCGG CpG islands as well as independent cytosine residues. These
protected cytosines are not deaminated during bisulfite modification.
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Figure 3.9 Sequence alignment of protected cytosines in DAX-1 promoter region of bisulfite
modified DNA. Not all cytosine residues are deaminated within the gDNA. Those that are not
deaminated by bisulfite modification are likely protected via methylation.
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Refining the focus to the specific CCGG CpG island of interest, differential conversion is
observed (Figure 3.10). Although the bisulfite modification severely damages the sequence in
certain places, an alignment can be identified based on specific base pairs. Overall, the least
degraded sequence came from the MCF10A noncancerous control cell line. Aligning this sequence
as best as possible against the NCBI wild type allowed for a clear alignment of the two cancerous
cell lines. Systematically looking at the CCGG sequence, this CpG island in the MCF10A cell line
is likely, this CpG island is hemi-methylated and therefore only partially protected via methylation.
The MCF7 breast cancer cells produced the most degraded sequence, in line with expectation from
previous research on the irregularities observed in breast cancer and DAX-1 expression. When
taking into account the preservation of both guanines and the successful conversion of one cytosine
to thymine, this island is likely hemi-methylated and mostly protected. Finally, this CpG island in
the A549 lung carcinoma cell line is thoroughly degraded, implying no protection by a methyl
group.
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Figure 3.10 Sequence alignment of CpG island in the DAX-1 promoter region of bisulfite
modified DNA. Highlighted in purple and gray are the regions used to identify the CpG island in
the bisulfite modified gDNA. The pink region indicates the CCGG CpG island being investigated
for protection via methylation.
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ChIP
Taking into consideration the size of the target region being amplified, a band of correct
molecular weight indicates the presence of the methyl-CpG binding domain protein at the CpG
islands located within the amplified regions. Honing in on protein occupancy in Region B located
shortly after the transcriptional start site, none of the MBD proteins were found to occupy the three
CpG islands located in this area of the DAX-1 promoter in the control MCF10A cell line (Figure
3.11). Conversely, all three MBD proteins were found in Region A and E, each containing 1 CpG
island, and Region C, which encompasses three CpG islands.
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Figure 3.11 PCR amplification product following ChIP in MCF10A non-cancerous
mammary gland control cells. The top row indicates results for MBD1, 2, and 3 binding. Within
these results, clear, on-target products are detected in PCR amplified regions A, C, and E.
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In comparison to the MCF10A ChIP products, the MCF7 products provide much more
intense bands in some regions, notably in Region B. MCF7 cells demonstrated occupancy by all
three MBD proteins and HDAC in all amplified promoter segments, excluding Region D (Figure
3.12).
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Figure 3.12 PCR amplification product following ChIP in MCF7 breast cancer cells. The top
row indicates results for MBD1, 2, and 3 binding. PCR products are detected in regions A, B, C,
and E. Region D only gives faint bands in the control settings indicating that it is not a target of
the MBD binding family of proteins.
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Following analysis of amplified ChIP products, a schematic of MBD protein occupancy
highlights the difference between control and cancerous breast cell lines (Figure 3.13). Most
striking is the occupancy of all the MBD proteins in Region B in the cancerous cell line but not
the control. This region contains three CCGG CpG islands and is located directly after the TATA
box. The presence of all three MBD proteins and HDAC indicates that this region is being
repressed via methylation in this cancer cell line (e.g. MCF7 cells, shown in the lower half of the
figure) but not in the control line (e.g. MCF10A, shown in the upper half of the figure).
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Figure 3.13 Model of methyl-CpG binding protein occupancy on the DAX-1 gene in MCF10A
control and MCF7 breast cancer cell lines. In both cell lines, there is a great deal of occupancy
by these proteins, however, there is a clear difference when focusing on amplified Region B.
Located near the TATA box, this region is repressed by MBD1, MBD2, and MBD3 in the breast
cancer cell line (MCF7) but is unoccupied in the control mammary gland cell line (MCF10A).
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Conclusion
Through bisulfite sequence analysis and chromatin immunoprecipitation, a model of the
difference between methylation status of CpG islands in the DAX-1 promoter region was
developed. The A549 cells were heavily modified at the CpG island of interest, concluding that
this region was not protected via methylation. This aligns with results from Chapter 2 that
identified this lung carcinoma cell line as the highest expressor of DAX-1 at the RNA and proteins
levels. Additionally, bisulfite sequencing gave a more precise depiction of what the MSRE analysis
revealed: the CpG island, located further upstream in the DAX-1 promoter, preceding the TATA
box, is unmethylated in the A549 lung carcinoma cells. Bisulfite sequencing also revealed that
MCF7 breast cancer and MCF10A noncancerous mammary gland cells are likely hemi-methylated
at this CpG island, confirming the results of MSRE analysis from Chapter 2. The hemi-methylation
in MCF7 cells could be correlated with the decreased expression of DAX-1 at the RNA and protein
levels previously observed in the first aim. Additionally, methyl-CpG-binding domain protein
occupancy in this region of the MCF10A DAX-1 promoter determined via ChIP confirmed the
hemi-methylation status concluded from bisulfite sequencing. Furthermore, ChIP analyses
highlighted a region following the TATA box where MBD occupancy varies between the
cancerous and noncancerous breast cells.
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Chapter 4: Discussion
The DAX-1 orphan hormone nuclear receptor has been shown to suppress tumor
progression in cancer metastasis. The hypothesis of this thesis was that DAX-1 gene expression is
differentially expressed across a survey of various cancers and that differential expression of DAX1 was, at least in part, due to the epigenetic repression via methylation. Methylation is a form of
epigenetic modification that can prevent transcription factors from binding to DNA in the promoter
region and thereby silencing gene expression. The implementation of qPCR and Western Blotting
confirmed that DAX-1 is being differentially expressed in the six human cell lines investigated.
Furthermore, methylation specific restriction enzyme analysis and bisulfite sequencing provided
evidence of methylation resulting in repressed gene expression. Finally, chromatin
immunoprecipitation confirmed a difference in methyl protein binding occupancy in cancerous
versus noncancerous cell types. Interestingly, methylation was also observed in the control cell
line. Though somewhat surprising, this is not altogether unexpected. The mammary glands are
composed of a frequently changing cellular landscape and the presence of DAX-1 fluctuates
(Judge, 2011). Additionally, the control cell line utilized was not ‘normal’ as it was isolated from
a diseased, but not tumorigenic, tissue.
Given the role of DAX-1 in mediating sexual determination in humans and regulating
differentiation of embryonic stem cells, it is not surprising it is epigenetically regulated. Studies
have shown that proper DNA methylation plays a key role in cell growth and differentiation, as
well as embryonic development (Iyer & McCabe, 2004; Lalli, 2014; Lalli et al., 1997; McCabe,
2007). Proper timing of DAX-1 expression is likely, at least in part, epigenetically controlled.
Previous studies in the Tzagarakis-Foster lab have demonstrated that the reintroduction of DAX1 at a physiological level slows the cell proliferation of MCF7 breast cancer cells and tumor
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formations in mouse xenograft models (Tzagarakis-Foster, manuscript in preparation).
Extrapolating the results shown in this project suggests that releasing the epigenetic control in a
cell line may, in turn, slow proliferation in tumor growth.
Cancer epigenetics is currently a cutting-edge field of research. Specifically, epigenetic
regulation of nuclear hormone receptors in tumorigenesis, has been the target of investigation for
new cancer therapies. The role of NHRs in cancer is complex and diverse. However, by targeting
methyl binding proteins to either release or induce epigenetic regulation of NHR gene expression,
alternative therapeutic targets may be developed in the future. Additionally, evaluating the degree
of methylation in tissue samples could be a viable biomarker for cancer screening.
As a nuclear hormone receptor, DAX-1 may potentially serve as a biomarker for the
increased likelihood of tumor development and cancer progression. Clinically, DAX-1 has been
extensively reviewed for its role in Adrenal Hypoplasia Congenita (AHC) and Dosage Sensitive
Sex reversal (DSS). Combined with its interdisciplinary connections to disease, as well as the rise
of nuclear hormone receptors, specifically in the orphan family, and methylation status as
oncogenic biomarkers, further investigation of the role of DAX-1 in hormone regulated cancers
could lead to future clinical applications. Future research integrating a more in depth bioinformatic
approach studying the DAX-1 epigenome and patient tissue samples could elucidate the importance
of DAX-1 in cancer tumor suppression, particularly in breast tissues. Accessing methylation
specific cancer databases and alignments from patient data against the wild type DAX-1 gene
would further determine the importance of methylation in the promoter region. Additionally,
understanding to what extent methylation represses gene expression could give rise to applications
that would release epigenetic control. In conclusion, the study of methylation status and NHRs
may uncover novel biomedical and therapeutic approaches to detecting and treating cancer.
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Appendix A: Supplementary Figures and Tables

Figure A.1 Restriction digest analysis of pGEM-T Easy and converted or control DNA
constructs. Following restriction digestion, constructs releasing a 300bp insert were submitted for
sequencing.
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Figure A.2 Sequence alignment of A549 bisulfite modified gDNA. Obtained from multiple
clones, there are few discrepancies (highlighted in yellow) between the multiple bisulfite modified
DNA samples.
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Figure A.3 Sequence alignment of MCF7 bisulfite modified gDNA. There are only minor
discrepancies (highlighted in yellow) between the multiple bisulfite modified DNA samples
obtained from plasmid clones.
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Figure A.4 Sequence alignment of MCF10A bisulfite modified gDNA. Obtained from multiple
clones, there are some discrepancies (highlighted in yellow) between the multiple bisulfite
modified DNA samples.
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Table A.1 Summary table of PCR running protocol parameters
Protocol
Cycling Parameters
95˚C x 3 minutes

1 Repeat

95˚C x 30 seconds
DAX-1 gDNA Detection via

55˚C x 30 seconds

PCR

72˚C x 1 minute

DAX-1 mRNA Expression via
qPCR

Repeat 35 times

72˚C x 5 minutes

1 Repeat

4˚C x infinite hold

1 Repeat

95˚C x 10 seconds

1 cycle

95˚C x 15 seconds
60˚C x 15 seconds
95˚C x 3 minutes

40 cycles
1 Repeat

95˚C x 20 seconds
Methylation Specific Restriction

61˚C x 30 seconds

Digest PCR

72˚C x 1 minute

Repeat 32-40 times

72˚C x 5 minutes

1 Repeat

4˚C x infinite hold

1 Repeat

95˚C x 3 minutes

1 Repeat

95˚C x 20 seconds
PCR Amplification of Bisulfite

52.3˚C x 30 seconds

Converted gDNA

72˚C x 60 seconds

Repeat 35 - 45 times

72˚C x 5 minutes

1 Repeat

4˚C x infinite hold

1 Repeat

95˚C x 3 minutes

1 Repeat

95˚C x 20 seconds
PCR Amplification on Isolated

61˚C x 30 seconds

ChIP Products

72˚C x 60 seconds

Repeat 50 times

72˚C x 5 minutes

1 Repeat

4˚C x infinite hold

1 Repeat
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Table A.2 Summary table of the primers used in PCR and qPCR
Target

Forward Primer

Reverse Primer

DAX-1 spanning Exon 1

5’ - CCC ACG ACA AAT

5’ - CTG CCC GAT GCT

(676) to Intron (1251) in

CAA GC - 3’

TTT GTG AG - 3’

Primers to detect genomic

gDNA:
Primers to detect
genomic DAX-1 spanning

5’ - CTC ACA AAA GCA

Intron (1232) to Intron (2399)

TCG GGC AG - 3’

5’ - GGG GTG AGC TGA
GGT CTC TAG - 3’

in gDNA:
Primers to detect DAX-1 gene

5’ - GAC TCC AGT GGG

5’ - ATG ATG GGC CTG

expression in qPCR

GAA CTC AG - 3’

AAG AAC AG - 3’

5’ - CCA TCA CCA TCT

5’ - AGA GAT GAT GAC

TCC AGG AGC G - 3’

CCT TTT GGC - 3’

Primer CpG Rich Region A

5’ - GAA GGA GGA AAG

5’ - AGC CCA GTT CTG

(Used for MSRE and ChIP)

TGT CCA GGA GCT C -3’

CCC AGT GGC TGC C -3’

Primer CpG Rich Region B

5’ - AGG GCA GCA TCC

5’ - TCT TCA CCA CAA

(Used for MSRE and ChIP)

TCT AGA AC - 3’

AAG CAG CA - 3’

Primer CpG Rich Region C

5’ - CTC AAA GCA AAC

5’ - CAC CTG TGG ACT

(Used for MSRE and ChIP)

GCA CGT G - 3’

CTT GAG CG - 3’

Primer CpG Rich Region D

5’ - GAA GAC CAC CCG

5’ - CAC TTG ATG GCT

(Used for MSRE and ChIP)

CAG CAG - 3’

TGG ACC TG - 3'

Primers to detect GAPDH
gene expression (positive
control):

Primer CpG Rich Region E
(Used for MSRE and ChIP)

5’ - AAT GCT GGA GTC
TGA ACA TCA GTA CCA
AGG - 3'

5’ - CCA CCC CAA CTC
TGC TGA GTT AGT C - 3'

Amplification of Bisulfite
Modified gDNA Region

5’ - AAG GAG GAA AGT

5’ - TGG AAA GAG TTG

Containing TATA Box and

GTT TAG GAG TTT - 3’

CAA CAG CA - 3’

First CpG Island
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